October 1 - December 31, 2009

1. Importation of Products Made Abroad by a Process Patented in Canada is Prohibited
   Eli Lilly and Company v. Apotex Inc., 2009 FC 991 (Gauthier, J.)
    
2. Disbursement Assessment Highlighting the Importance of Thorough Documentation
   Fournier Pharma Inc. v. Canada (Minister of Health), 2009 FC 1004 (Stinson, Assessment Officer)
    
3. A Respondent That Was Added Pursuant to the NOC Regulations is Not Jointly and Severally Liable for Costs 
   Sanofi-Aventis Canada Inc. v. Novopharm Limited and The Minister of Health and Schering Corporation, 2009 FC 1003 (Preston, Assessment Officer)
    
4. Selection Patent Held Invalid – No Evidence of Advantage and No Sound Prediction
   Eli Lilly Canada Inc., Eli Lilly and Company, Eli Lilly and Company Limited and Eli Lilly SA v. Novopharm Limited, 2009 FC 1018 (O’Reilly, J.)
    
5. Motion to Amend Pleadings in Conflict Proceedings Allowed:  Relief Based on Lack of Candour in Patent Application Prosecution Submissions Might Succeed
   Mycogen Plant Science, Inc. v. Bayer Bioscience N.V., 2009 FC 1013 (Hughes, J.)
    
6. Decisions of Case Management Prothonotaries Entitled to Discretion Unless Prothonotary Was Clearly Wrong.
   Astrazeneca Canada Inc., et al. v. Novopharm Limited and Minister of Health, 2009 FC 1020 (Kelen, J.)
    
7. Failed Appeal of a Judgment Dismissing a Trade-mark Application 
   Masterpiece Inc. v. Alavida Lifestyles Inc., 2009 FCA 290 (Sexton J.A., Layden-Stevenson J.A., Trudel J.A.)
    
8. Irreparable Harm Test No Different for Copyright, Trade-marks or Passing Off
   Eli Lilly Canada Ltd. v. Apotex Inc. 2009 FC 1053 (Martineau, J.)
    
9. Allegations in an NOA should be assessed as of the date of the hearing –not when served
   Sanofi-Aventis Canada v. Hospira Healthcare Corporation and the Minister of Health, 2009 FC 1077 (Zinn, J.)
    
10. Unopposed Appeal From Trade-mark Hearing Officer On Use
    Loro Piana S.P.A. v. Canadian Council of Professional Engineers, 2009 FC 1095 (Near, J.)
    Loro Piana S.P.A. v. Canadian Council of Professional Engineers, 2009 FC 1096 (Near, J.)
     
11. Program Completion Designations Expunged as Trade-marks in Summary Judgment
    College of Traditional Chinese Medicine Practitioners and Acupuncturists of British Columbia v. Council of Natural Medicine College of Canada, 2009 FC 1110 (O’Keefe, J.)
     
12. Dismissal of Action Reconsidered Reviving Part of Action 
    Atomic Energy of Canada Limited v. Areva NP Canada Ltd. and Societe des Participations du Commissariat A L'Energie Atomique, 2009 FC 1119 (Zinn, J.)
     
13. Costs in a Contested Patent Infringement Action
    Sanofi-Aventis Canada Inc. v. Apotex Inc., 2009 FC 1138 (Snider, J.)
    Sanofi-Aventis Canada Inc. v. Novopharm Limited, 2009 FC 1139 (Snider, J.)
     
14. Les objections lors d’un contre-interrogatoire 
    Eurocopter S.A.S. c. Bell Helicopter Textron Canada Limitée, 2009 CF 1142 (Tremblay-Lamer, J.)
     
15. Les objections lors d’un contre-interrogatoire – Prise 2
    Eurocopter S.A.S. c. Bell Helicopter Textron Canada Limitée, 2009 CF 1142 (Tremblay-Lamer, J.)
     
16. Impecuniosity Found on Appeal in Motion for Security for Costs
    Nicholas v. Environmental Systems (International) Limited, 2009 FC 1160 (Mosley, J.)
     
17. Motion to Amend a Judgment From NOC Proceedings and Cross-motion to Adjourn Dismissed
    Pfizer Canada Inc. v. The Minister of Health and Ratiopharm Ltd., 2009 FC 1165 (Hughes, J.)
     
18. Dispute Over Secondary Mark Not a “Special Circumstance” to Excuse Non-use of Registered Mark
    Jose Cuervo S.A. de C.V. v. Bacardi & Company Limited and The Registrar of Trade-marks, 2009 FC 1166 (Kelen, J.)
     
19. PMNOC – A Patent Listed Under Section 4(2)(b) Must Claim All Medicinal Ingredients in the Formulation Approved in the NOC
    Bayer Inc. v. The Minister of Health (AG Canada)  2009 FC 1171 (Russell J.)
     
20. Appeal Relating to Leave to File Additional Evidence Granted
    Janssen-Ortho Inc. and Alza Corporation v. Novopharm Limited and the Minister of Health., 2009 FC 1179 (Zinn, J.)
     
21. New Evidence on Appeal Must Be in the Interests of Justice 
    Pfizer Limited v. Ratiopharm Inc. 2009 FCA 338 (Layden-Stevenson, J.A.)
     
22. Proposed Intervention Fails to Bring a Perspective to the Proceedings Different From That of the Parties
    Pfizer Limited v. Ratiopharm Inc., 2009 FCA 339 (Layden-Stevenson, J.A.)
     
23. Appeal of a Trade-mark Opposition Board Decision Dismissed
    Simpson Strong-Tie Company, Inc. v. Peak Innovations Inc., 2009 FC 1200 (Snider, J.)
     
24. Canadian Federal Court Clarifies Good Faith Requirement in Patent Prosecution
    Lundbeck Canada Inc. v. ratiopharm Inc., 2009 FC 1102 (Mactavish, J.)
     
25. Limits on Double Costs
    McKay v. Weatherford Canada Ltd. et al, 2009 FCA 343 (Stinson, Assessment Officer.)
     
26. Appeal Granted In Light Of New Evidence
    Advance Magazine Publishers v. Wise Gourmet Inc. 2009 FC 1208 (Mainville, J.)
     
27. Opposition Appeal Dismissed Partly Due to Lack of Licensing Evidence
    Advance Magazine Publishers Inc. v. Farleyco Marketing Inc., 2009 FCA 348 (Blais C.J., Noël J.A., and Layden-Stevenson J.A.)
     
28. Abuse of Process Considered By the Federal Court
    Tractor Supply Co. of Texas LP v. TSC Stores L.P., 2009 FCA 352 (Blais, C.J., Noël, J.A., Layden-Stevenson, J.A.)
     
29. Assessment Officer Makes Various Findings Concerning Allowable Costs and Disbursements
    Bayer AG, Bayer Healthcare AG and Bayer Inc. v. Novopharm Limited and The Minister of Health, 2009 FC 1230 (Bruce Preston, Assessment Officer)
     
30. Product Claims Constitute Double Patenting Under the Old Act, When Product-by-Process Claims Have Been Granted in the Parent Patent
    Bayer Schering Pharma Aktiengesellschaft v. Canada (Attorney General), 2009 FC 1249 (Boivin, J.)
     
31. Federal Court Provides Guidance Calculating Interest on Levies and Penalties
    Canadian Private Copying Collective v. Data Media Products Inc., 2009 FC 1277 (Simpson, J.)
     
32. Motion for Consolidation Dismissed
    Sanofi-Aventis Canada Inc. v. Novopharm Limited, 2009 FC 1285 (Snider J.)
     
33. Application for Prohibition (PMNOC) Granted for Latanoprost/XALATAN®
    Pfizer Canada Inc. and Pharmacia Atkiebolag v. Canada (Minister of Health) and Pharmascience Inc., 2009 FC 1294 (Heneghan, J.)
     
34. Court Upholds Prothonotary’s Decision for Broad Disclosure in Affidavit of Documents
    Eli Lilly Canada Inc. and Eli Lilly and Company v. Hospira Healthcare Corporation 2009 FC 1316 (Lemieux, J.)